X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
index medicus (5) 5
bone marrow (3) 3
female (3) 3
germany (3) 3
male (3) 3
medicine, general & internal (3) 3
middle aged (3) 3
aged (2) 2
aged, 80 and over (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
cancer (2) 2
chemotherapy (2) 2
clinical trials (2) 2
dose cytarabine (2) 2
elderly-patients (2) 2
leukemia (2) 2
leukemia, myeloid, acute - diagnosis (2) 2
leukemia, myeloid, acute - drug therapy (2) 2
leukemia, myeloid, acute - mortality (2) 2
mortality (2) 2
review (2) 2
review article (2) 2
risk assessment (2) 2
risk factors (2) 2
stem-cell transplantation (2) 2
time factors (2) 2
transplants & implants (2) 2
treatment outcome (2) 2
1st complete remission (1) 1
1st remission (1) 1
abridged index medicus (1) 1
acute myelogenous leukemia (1) 1
acute myeloid leukemia (1) 1
acute myeloid-leukemia (1) 1
acute promyelocytic leukemia (1) 1
adult (1) 1
age factors (1) 1
allografts (1) 1
aml (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
apoptosis (1) 1
arsenic trioxide (1) 1
automation (1) 1
blood cells (1) 1
bone-marrow (1) 1
breast-cancer (1) 1
cd34 antigen (1) 1
cell biology (1) 1
chemotherapy, adjuvant (1) 1
chronic myelomonocytic leukemia (1) 1
classification (1) 1
clinical decision-making - methods (1) 1
clinical trials as topic - methods (1) 1
combination (1) 1
comorbidity index (1) 1
conferences (1) 1
constitutive activation (1) 1
cooperative-oncology-group (1) 1
council aml11 trial (1) 1
criteria (1) 1
cytarabine (1) 1
cytarabine - administration & dosage (1) 1
cytarabine - therapeutic use (1) 1
cytology (1) 1
daunorubicin - administration & dosage (1) 1
daunorubicin - therapeutic use (1) 1
design of experiments (1) 1
disease progression (1) 1
disease-free survival (1) 1
double-blind method (1) 1
down-regulation (1) 1
electronic mail (1) 1
eligibility (1) 1
essential thrombocythemia (1) 1
european leukemianet (1) 1
expression (1) 1
favorable prognosis (1) 1
flt3 mutations (1) 1
geriatric assessment - methods (1) 1
graft rejection - etiology (1) 1
graft rejection - prevention & control (1) 1
granulopoiesis (1) 1
growth (1) 1
health aspects (1) 1
hematology, oncology and palliative medicine (1) 1
hematopoietic stem cell transplantation (1) 1
hematopoietic stem cells (1) 1
hematopoietic-cell transplantation (1) 1
hemopoiesis (1) 1
high-dose cytarabine (1) 1
hipaa privacy rule (1) 1
hospital information systems (1) 1
hospitals (1) 1
hypertension (1) 1
immunoprecipitation (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2000 - 2008
Journal Article
DEUTSCHES ARZTEBLATT INTERNATIONAL, ISSN 1866-0452, 12/2011, Volume 108, Issue 51-52, pp. 863 - U11
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.